clobetasol and Dermatitis

Topical corticosteroids (TCS) are the mainstay of psoriasis treatment. Safety concerns may limit use. Combination with tazarotene may optimize efficacy and minimize safety and tolerability concerns.. Investigate safety and efficacy of halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion in moderate-to-severe plaque psoriasis.. Two multicenter, randomized, double-blind, vehicle-controlled phase 3 studies (N=418). Subjects randomized (2:1) to HP/TAZ lotion or vehicle once-daily for 8 weeks, 4-week follow-up. Primary efficacy assessment: treatment success (at least a 2-grade improvement from baseline in IGA score and 'clear' or 'almost clear'). Safety and treatment emergent AEs evaluated throughout.. HP/TAZ lotion demonstrated statistically significant superiority over vehicle as early as week 2 (P equals 0.002). By week 8, 40.6% of subjects were treatment successes compared with 9.9% on vehicle (P less than 0.001). A third of subjects remained treatment successes post-treatment. HP/TAZ lotion was also superior in reducing psoriasis signs and symptoms, and Body Surface Area (BSA) involvement. Most frequently reported treatment related AEs were contact dermatitis (6.3%), application site pain (2.6%), and pruritus (2.2%).. No data were collected beyond the 4-week follow-up.. HP/TAZ lotion provides synergistic efficacy that is both rapid and sustained, with good tolerability and safety over 8 weeks use. J Drugs Dermatol. 2018;17(8):855-861.

Topics: Clinical Trials, Phase III as Topic; Clobetasol; Dermatitis; Dermatologic Agents; Drug Combinations; Female; Humans; Male; Multicenter Studies as Topic; Nicotinic Acids; Pain; Psoriasis; Randomized Controlled Trials as Topic; Severity of Illness Index; Skin Cream; Treatment Outcome

Topical steroid creams and ointments have been available as over-the-counter (OTC) medications for the self treatment of acute dermatitis and other steroid responsive skin disorders for more than ten years. Despite earlier fears, widespread availability and use of these creams is not associated with clinically significant adverse effects. In dermatological practice, hydrocortisone 1% remains the mainstay of treatment for facial eczema, but it is often not effective in eczema affecting other body areas. Eumovate(TM) (clobetasone butyrate 0.05%) cream has recently been made available as a pharmacy medication for the short-term management of acute eczema and allergic dermatitis by adults and children aged 10 or older, based on evidence derived from clinical trials involving over 3500 patients. This review summarises the key efficacy and safety data derived from 29 clinical trials and the post-licensing pharmacovigilance safety information, which supported the reclassification of this product for OTC use. These data show clobetasone butyrate 0.05% is more effective than 1.0% hydrocortisone in the treatment of eczema and more effective than flurandrenolone 0.0125% (p=0.01%) and a potent topical steroid hydrocortisone butyrate (p<0.05), in the treatment of psoriasis. A review of the effect of topical steroids on skin thickness concluded that, following short term application, there was no clinically significant difference between hydrocortisone 1.0% and clobetasone butyrate 0.05% in terms of potential for skin thinning. Similarly, even under extreme conditions, clobetasone butyrate 0.05% has negligible systemic absorption and has almost no effect on HPA axis function.

Topics: Acute Disease; Administration, Cutaneous; Administration, Topical; Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents; Clobetasol; Dermatitis; Humans; Hydrocortisone; Nonprescription Drugs; Ointments; Randomized Controlled Trials as Topic; Self Medication

Postinflammatory hyperpigmentation (PIH) is the most common adverse effect of laser treatment in dark-skinned individuals. Little is known whether PIH can be prevented or minimised. The objective of this study was to investigate the effect of short-term application of topical corticosteroids on the incidence of PIH after ablative fractional resurfacing in Asians. Forty subjects with skin phototype IV and atrophic acne scars were treated with a fractional CO2 laser on both sides of the face. Post-operatively, clobetasol propionate 0.05% ointment was applied to one randomly selected side of the face for the first 2 days, followed by an application of petrolatum jelly for the rest of the week (petrolatum was applied to the other side for 7 days). Assessments on the clinical outcome, the wound healing process and the occurrence of PIH were obtained once weekly for the first month and at 2 and 3 months post-treatment. The side of the face treated with petrolatum alone had significantly (p < 0.001) higher incidence of PIH (75%) after laser irradiation than the side of the face treated with topical corticosteroids and petrolatum (40%). The PIH occurring on the petrolatum-treated sides had significantly higher intensity (p < 0.001) and was spread over a significantly larger area (p < 0.001), compared with the corticosteroid- and petrolatum-treated sides. In conclusion, a short-term application of topical corticosteroids postoperatively is associated with a decreased risk of PIH after ablative fractional resurfacing.

Topics: Acne Vulgaris; Administration, Cutaneous; Adrenal Cortex Hormones; Asian People; Cicatrix; Clobetasol; Dermatitis; Dermatologic Surgical Procedures; Female; Humans; Hyperpigmentation; Laser Therapy; Lasers, Gas; Male; Single-Blind Method; Skin Pigmentation; Thailand; Time Factors; Treatment Outcome

Clobetasol propionate shampoo is effective and safe in treatment of scalp psoriasis (SP). Gene expression profiling of psoriatic skin biopsies led to the identification of numerous disease-related genes. However, it remained unknown whether the gene expression profile of hair follicles of SP patients was also affected.. To determine whether psoriasis-related genes are differentially regulated in the hair follicles of SP patients and whether the modulation of these genes can be correlated with clinical severity scores.. A single arm, open study was conducted in three centres. SP patients received daily treatment with clobetasol propionate shampoo. At Baseline, Weeks 2 and 4, investigators assessed clinical severity parameters and collected scalp hair follicles in anagen phase. Total RNA extracted from hair follicles was used to determine the expression level of 44 genes, which were reported previously to be upregulated in the skin of psoriasis patients.. RNA of good quality and sufficient quantity was obtained from hair follicles of psoriasis patients and healthy volunteers (HV). The expression level of 10 inflammation-related genes was significantly increased in psoriatic hair follicles. The patient's exploratory transcriptomic score, defined as the mean fold modulation of these 10 genes compared with HV, correlated with clinical severity scores. Clobetasol propionate shampoo was effective in decreasing both the exploratory transcriptomics and the clinical severity scores.. Hair follicles of SP patients are affected by the inflammatory process. The change in the expression level of inflammation-related genes correlates with the severity of the disease.

Topics: Adult; Biomarkers; Clobetasol; Dermatitis; Drug Resistance; Gene Expression; Gene Expression Profiling; Glucocorticoids; Hair Follicle; Hair Preparations; Humans; Psoriasis; Scalp; Severity of Illness Index

Topics: Administration, Topical; Aged; Anti-Inflammatory Agents; Clobetasol; Dermatitis; Female; Glucocorticoids; Humans; Hypertension; Ischemia; Male; Necrosis; Skin Ulcer

Dermatoses that interfere with the normal use of a stoma appliance are common. When preventable causes, such as infection or allergy, are not identified, barrier preparations or topical steroids have been used. However, topical medicaments formulated in a cream or ointment base will cause stoma bags to detach, resulting in leaks.. Our purpose was to investigate the efficacy and suitability of corticosteroids in aqueous/alcohol lotions in the management of peristomal dermatoses.. A clinic run by a dermatologist and 2 stoma nurses was created. Patients with a variety of noninfective, inflammatory dermatoses were treated with topical corticosteroid lotions up to a maximum of 4 weeks, with occasional use thereafter in some cases.. Topical, aqueous/alcohol, corticosteroid lotions have been used in 60 patients and have proved particularly useful for the treatment of irritant dermatitis, pyoderma gangrenosum, psoriasis, and constitutional eczema. After the initial treatment course, occasional applications, approximately every 2 weeks, may be necessary to control the skin disorder. This low frequency of application minimizes the risk of side effects so that we have not identified local or systemic side effects in any of the patients treated so far.. Topical corticosteroids formulated in aqueous alcohol lotion are effective and acceptable treatments for peristomal dermatoses. If used appropriately, the risk of side effects is low.

Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Clobetasol; Dermatitis; Glucocorticoids; Humans; Surgical Stomas

The effects of topical indomethacin and clobetasol propionate on erythema and oedema following low-dose cryotherapy to normal skin were examined using a single-blind technique. Both agents significantly reduced erythema, but neither had a significant effect on oedema. A further, controlled, double-blind study comparing topical indomethacin and inert gel base was performed after cryotherapy to hand warts. In this study, topical indomethacin had no significant effect on post-cryotherapy oedema, erythema, pain or blister formation 48 and 96 h after treatment. Both potent topical steroids and cyclo-oxygenase inhibitors reduce erythema after low-dose cryotherapy. In clinical practice, there is no evidence that topical indomethacin significantly inhibits the inflammatory response to cryotherapy.

Topics: Administration, Topical; Adolescent; Adult; Child; Clobetasol; Cryotherapy; Dermatitis; Double-Blind Method; Edema; Erythema; Female; Humans; Indomethacin; Male; Middle Aged; Postoperative Complications; Skinfold Thickness; Warts

The efficacy and safety of 0.05% halobetasol propionate ointment were evaluated in patients with chronic atopic or other eczematous dermatoses in two vehicle-controlled, double-blind studies: a paired-comparison study in 124 patients (study A) and a parallel-group study in 100 patients (study B). In study A, patients applied both treatments twice daily for 2 weeks and were evaluated by investigators on days 0, 7, and 14 with 0 to 3 severity scales and by self-assessment with two 5-step end-of-treatment rating scales. In study B, patients applied treatments twice daily for 2 weeks, and investigators made evaluations on days 0, 3, 7, and 14 with 0 to 6 scales and also made a 5-step end-of-treatment physician's global assessment. In study A, both severity scores and patient ratings favored halobetasol propionate significantly on days 7 (p less than or equal to 0.0013) and 14 (p less than 0.0001); in study B, severity scores on days 3 (p less than or equal to 0.045, pruritus, erythema, and overall lesion severity), 7, and 14 (p less than 0.001, all comparisons) also favored halobetasol propionate significantly, and global assessments showed complete resolution or marked improvement for 83% of patients using halobetasol propionate versus 28% of those using vehicle (p less than 0.0001). No instances of systemic effects or skin atrophy were reported in either study. We conclude that 0.05% halobetasol propionate ointment is highly effective and well tolerated in the treatment of the conditions studied, with the rapid action and high degree of clearing associated with superpotent corticosteroid formulations.

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Clobetasol; Dermatitis; Dermatitis, Atopic; Eczema; Female; Humans; Male; Middle Aged; Neurodermatitis; Ointments; Pharmaceutical Vehicles; Remission Induction; Safety; Treatment Outcome; United States; Vasoconstrictor Agents

Six investigators evaluated 0.05% halobetasol propionate cream and its vehicle in 111 patients with chronic atopic dermatitis and several other eczematous dermatoses. Patients applied treatment twice daily to bilateral lesions for 14 days. Investigators graded pruritus, erythema, scaling, papulation, and lichenification using 4-point severity scales on days 0, 7, and 14. On day 14 patients provided an assessment of efficacy for both treatments. Statistically significant differences favoring halobetasol propionate over the vehicle were seen for all signs and symptoms (p less than 0.001). Substantial improvements were achieved by the active treatment by day 7 (p less than 0.001). Patients assessments of efficacy were significantly higher for halobetasol cream than for vehicle (p less than 0.001). No instances of systemic effects or skin atrophy were reported and adverse experiences were limited to burning or stinging and other minor, nonspecific complaints distributed uniformly between active treatment and vehicle. These results demonstrate that 0.05% halobetasol propionate cream is highly effective in the treatment of atopic dermatitis and other eczematous dermatoses.

Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Chronic Disease; Clobetasol; Dermatitis; Dermatitis, Atopic; Double-Blind Method; Eczema; Female; Humans; Male; Middle Aged; Neurodermatitis; Patient Satisfaction; Pharmaceutical Vehicles; Remission Induction; Safety; Vasoconstrictor Agents

A double-blind, randomized, placebo-controlled trial was carried out comparing the effects of clobetasol propionate ointment and the ointment base on the inflammation induced by cryotherapy of basal cell carcinomata and warts. A single application of the steroid was shown to be significantly better at reducing erythema, pain and swelling than the ointment base.

Topics: Adolescent; Adult; Aged; Betamethasone; Carcinoma, Basal Cell; Clinical Trials as Topic; Clobetasol; Cryosurgery; Dermatitis; Double-Blind Method; Erythema; Humans; Middle Aged; Ointments; Skin Diseases; Skin Neoplasms; Warts

Topics: Clinical Trials as Topic; Clobetasol; Dermatitis; Halcinonide; Humans; Pregnenediones; Psoriasis

Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Betamethasone; Clinical Trials as Topic; Clobetasol; Dermatitis; Double-Blind Method; Female; Humans; Male; Middle Aged

In a double-blind investigation, 36 patients suffering from various steroid-reponsive dermatoses were treated twice daily for three weeks either with 0-05% betamethasone 17,21-dipropionate cream or with 0-05% clobetasol propionate cream. Results showed both products to be highly effective in terms of onset of action and efficacy and no statistical differences were found (p greater than 0-1).

Topics: Administration, Topical; Adolescent; Adult; Aged; Betamethasone; Clinical Trials as Topic; Clobetasol; Dermatitis; Drug Tolerance; Female; Humans; Male; Middle Aged

Although animal models have been extensively used to evaluate human topical therapeutics, they exhibit marked physiological differences to human skin. Our objective was to develop a human ex vivo skin culture model to explore the pathophysiology of inflammatory dermatoses and for preclinical testing of potential therapeutic treatments. Ex vivo skin barrier integrity and metabolic activity was retained for 5 days and stimulation of T-helper cells (Th1), which produce proinflammatory cytokines, provided inflammatory responses similar to those reported from in vivo biopsy. Tissue responses to established therapies of pimecrolimus (Elidel) and clobetasol propionate (Dermovate) were evaluated using the human ex vivo skin culture, assessing pharmacodynamic changes in gene expression alongside the pharmacokinetics of drug penetration with both products showing time dependent efficacies. The translational utility of the human ex vivo skin culture model of inflammatory dermatoses was demonstrated through comparison with an in vivo clinical study, with similar reductions in inflammatory gene expression recorded for both drug treatments. Thus, this model can reduce, replace or refine animal testing and also mitigate the risk of failure in costly and time-consuming clinical trials associated with novel topical therapeutic development.

Topics: Animals; Biopsy; Clobetasol; Cytokines; Dermatitis; Humans; Skin

This study was designed to establish quality standards of Burnet gels and investigate the effects and mechanism of Burnet gels on steroid-dependent dermatitis (HDD) in guinea pigs.. HPLC was used to determine the content of gallic acid, Gentiopicrin, and paeonol. A total of 48 male guinea pigs were recruited and randomly divided into control group, model group, tacrolimus ointment group, and Burnet gel group (Low, medium, and high concentration). The HDD guinea pig model was established by the 0.5% clobetasol propionate tincture. After HDD model establishment, control group and model group smeared normal saline and the rest of the group with corresponding drugs for three weeks. The contents of IFN-. The content of gallic acid, Gentiopicrin, and paeonol was 0.30 mg/g, 1.06 mg/g, and 0.56 mg/g. Compared with the normal group, the IFN-. Burnet gels can improve guinea pig HDD model, and the mechanism may be related to inhibiting skin inflammation and promoting the formation of epidermal skin barrier.

Topics: Acetophenones; Animals; Caspase 14; Clobetasol; Dermatitis; Gallic Acid; Gels; Guinea Pigs; Immunoglobulin E; Interleukin-4; Iridoid Glucosides; Male; Ointments; Saline Solution; Sanguisorba; Tacrolimus

The goal of this study was to elucidate the anti-pruritic and anti-inflammatory efficacy of ruxolitinib cream in experimentally-induced dermatitis. Atopic dermatitis (AD), the most common chronic relapsing inflammatory skin disease, significantly impairs patients' quality of life, with pruritus being a common complaint. The sensation of itch results from the interplay between epidermal barrier dysfunction, upregulated immune signaling and the activation of the central nervous system. The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway plays a central role in pro-inflammatory cytokine signaling in AD. Ruxolitinib cream is a potent and selective JAK1/2 inhibitor currently undergoing clinical evaluation in adults with mild-to-moderate AD (NCT03745638, NCT03920852 and NCT03745651). The efficacy of ruxolitinib cream was tested in murine models of acute and chronic dermatitis and was also characterized in an

Topics: Administration, Cutaneous; Animals; Betamethasone; Clobetasol; Cytokines; Dermatitis; Disease Models, Animal; Drug Eruptions; Drug Evaluation, Preclinical; Female; Fluorescein-5-isothiocyanate; Grooming; Humans; In Vitro Techniques; Interleukin-33; Janus Kinase Inhibitors; Lymphocyte Subsets; Mice; Mice, Inbred BALB C; Mice, Transgenic; Nitriles; Ointments; Organ Culture Techniques; Pruritus; Pyrazoles; Pyrimidines; Random Allocation; Signal Transduction; Skin; Specific Pathogen-Free Organisms; T-Lymphocytes, Helper-Inducer; Thymic Stromal Lymphopoietin; Transcriptome

Topics: Adolescent; Adult; Clobetasol; Dermatitis; Diagnosis, Differential; Female; Humans; Lichenoid Eruptions; Male; Tacrolimus

Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Biological Factors; Clobetasol; Dermatitis; Humans; Injections, Subcutaneous; Medication Adherence; Ointments

Topics: Adult; Anticonvulsants; Clobetasol; Dermatitis; Drug Eruptions; Eating; Female; Glucocorticoids; Granuloma; Humans; Migraine Disorders; Skin; Skin Diseases; Topiramate; Treatment Outcome

Topics: Abdomen; Amoxicillin-Potassium Clavulanate Combination; Anti-Inflammatory Agents; Benzimidazoles; Carnitine; Clobetasol; Dermatitis; Edema; Erythema; Female; Humans; Injections, Subcutaneous; Keratosis; Lipolysis; Mesotherapy; Middle Aged; Peptides; Phosphatidylcholines; Piperidines; Prednisone; Subcutaneous Fat; Thigh

Although topical corticosteroid ointments were once viewed as the best vehicle for treating inflammatory skin diseases, the recognition of the problem of poor compliance and patients' preferences for other vehicles has led to the development of corticosteroid products in alternative formulations.. To describe patterns of use of newer vehicle formulations including foams, shampoos, sprays, and lotions for the treatment of psoriasis and other dermatoses.. The use of non-traditional vehicles was identified using visit with diagnoses for psoriasis and other dermatoses from the National Ambulatory Medical Care Survey 2000-2010 data. Trends in corticosteroid vehicles mentions were evaluated over the study period to determine how the use of non-traditional vehicles has changed. The odds ratios of being prescribed a nontraditional vehicle were reported for patient and office-based characteristics of visits.. Approximately 2.3% and 1.9% of visits mentioned foam and other non-traditional vehicles (shampoo, lotion, spray), respectively. The use of corticosteroids in shampoo, lotion, or spray preparations increased by 0.5% annually (p=0.008) but did not significantly change for corticosteroids in a foam preparation (p=0.10). Psoriasis and seborrheic dermatitis were the leading diagnoses at visits prescribed corticosteroids in nontraditional vehicles. Dermatologists were more likely than non-dermatologists to prescribe foam products [OR: 8.4 (3.6, 19.9)] or clobetasol in another non-traditional vehicle [OR: 49.7 (10.3, 240.5)].. Product vehicle was not specified for all corticosteroids.. Although there was increasing use of non-traditional vehicles, the rate of use has remained low. Dermatologists appear to have greater familiarity with the use of these newer vehicle formulations than do physicians in other specialties.

Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Clobetasol; Dermatitis; Dermatitis, Seborrheic; Dermatologic Agents; Female; Humans; Male; Medication Adherence; Pharmaceutical Vehicles; Psoriasis; Skin Cream

A patient is described with dermatitis artefacta, which is a common psychocutaneous disorder whereby a fully-aware patient self-inflicts injury to their skin. The motives for their behaviour can vary and the patient always tries to hide the responsibilities for their actions. In this case report, serial use of standardised photography provided strong evidence to support the diagnosis of dermatitis artefacta. The fluorescent properties of Trimovate® Cream under Wood's light examination corroborated the diagnosis. Trimovate® Cream was applied to the skin surrounding the injuries and the limb was occluded with four layers of bandages. Traces of Trimovate® Cream were seen under Wood's light on the outer layers of the bandage. This suggested transfer of the cream from the occluded skin surface by the patient's fingers whilst tampering with the dressings. This case report shows how serial photography and imaging using ultraviolet (UV) fluorescence can provide evidence to support the diagnosis of dermatitis artefacta.

Topics: Anti-Inflammatory Agents; Clobetasol; Dermatitis; Humans; Male; Middle Aged; Photography; Self-Injurious Behavior; Ultraviolet Rays

A five and a half year-old girl presented with a reddish-brown plaque on her right anterior tibia, first observed 1 year previously and without any history of injury or insect bite. Histological examination showed a dense dermal infiltrate composed of plasma cells and small lymphocytes, combined with lymphocytic exocytosis in the epidermis and interface dermatitis. In addition, a second biopsy found small epithelioid granulomas within the lymphoplasmocytic infiltrate. Infection was ruled out. No clonality was found. None of the treatments attempted was successful (antibiotics and steroids), and the lesion was stable but did not improve for 4 years. The same features typical of lymphoplasmocytic pseudolymphoma were observed on a third biopsy. A diagnosis of "pretibial lymphoplasmocytic plaque" was made on the basis of clinical and histological findings. Recently, 3 other cases of this type of lymphocytic and plasma cell cutaneous infiltrate with very distinctive clinical and histopathological features have been reported in children. Our case is instructive because it presents new and as yet undocumented histopathologic features including a lichenoid reaction with vacuolization of the basal cell layer and numerous apoptotic bodies, apparent in 2 of the 3 biopsies, and hypervascularity with thick-walled blood vessels lined with plump endothelial cells in the upper dermis. The clinicopathological presentation of these cases, including ours, is homogenous suggesting a specific entity described as "pretibial lymphoplasmocytic plaque in children". This seems to be a benign, chronic, reactive process, probably arising secondary to a local response to an unknown antigen.

Topics: Child, Preschool; Clobetasol; Dermatitis; Dermis; Diagnosis, Differential; Female; Glucocorticoids; Humans; Leg Dermatoses; Lymphocytes; Plasma Cells; Pseudolymphoma; Treatment Outcome

Cutaneous eruptive xanthomas are characteristics lesions of hyperlipidemia. Rarely,these lesions may present with prominent leukocytoclasis as seen in papular neutrophilic xanthomas, which have been described in HIV positive and immunocompromised patients. Herein we describe a patient with eruptive neutrophilic xanthomas with neither hyperlipidemia nor immunocompromise. Moreover, these lesions improved with sun and UV light exposure.

Topics: Acyclovir; Anemia; Clobetasol; Colchicine; Dermatitis; Humans; Male; Middle Aged; Neutrophils; Prednisone; Pruritus; Testosterone; Ultraviolet Therapy; Valacyclovir; Valine; Xanthomatosis

Topical steroids became available, without prescription, in the U.K. in 1987, with hydrocortisone 1% cream first being licensed for irritant contact dermatitis and reactions to insect bites. Since then the number of indications for nonprescription hydrocortisone use has increased and clobetasone has also become available as an over-the-counter (OTC) medicine. Little has been reported about how OTC steroids are used by community pharmacy clients.. We determined how OTC topical steroids are applied by patients, their demographic profile, the products used and the conditions treated, how frequently products were applied and how regularly purchased. The extent to which off-label use takes place was explored.. A patient-completed questionnaire study was used in 100 branches of a national pharmacy in Great Britain.. Questionnaires were completed and returned by 315 clients (16%). Eczema (192 cases, 61%) and dermatitis (66 cases, 21%) were the conditions most frequently treated. Nottingham Eczema Severity Scores calculated for 228 eczema and dermatitis sufferers shows that 164 patients (72%) had mild eczema. Those with more severe eczema were more likely to use clobetasone than hydrocortisone. The use of topical steroids outside OTC marketing authorization guidelines was widespread; however, no patient reported any adverse effects or deterioration in condition following steroid use.. OTC topical steroids are used mainly to treat eczema and dermatitis. Almost 50% of users treating these conditions exceed the limits of the rather restrictive OTC marketing authorization. Clinicians should be aware of the potential for adverse effects as a result of patients self-medicating with hydrocortisone or clobetasone for an extended period.

Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Child; Child, Preschool; Clobetasol; Contraindications; Dermatitis; Drug Administration Schedule; Eczema; Female; Glucocorticoids; Humans; Hydrocortisone; Infant; Male; Middle Aged; Nonprescription Drugs; Patient Satisfaction; Self Administration; Skin Diseases; Surveys and Questionnaires; United Kingdom

Chondrodermatitis nodularis chronica helicis is characterized by the presence of small, intensely painful nodules on the free border of the helix of the ear with unknown origin. The lesion is typically localized unilaterally on the right ear. Pressure and trauma may play a role.

Topics: Cartilage Diseases; Clobetasol; Dermatitis; Ear Cartilage; Ear Diseases; Female; Humans; Middle Aged; Ointments

A group of 16 male patients with infertility had dermatitis of the scrotum and groins giving lichenified oedematous skin; the resulting thickening and loss of rugosity produced a characteristic appearance that we have termed wash leather scrotum. Treatment of the dermatosis resulted in an improvement in sperm count and motility in most patients, and 5 couples produced one or more pregnancies.

Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Clobetasol; Dermatitis; Dermatitis, Seborrheic; Female; Humans; Male; Neomycin; Nystatin; Oligospermia; Pregnancy; Scrotum; Sperm Count